A Pivotal (phase IIb), Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Protocol No
SOLIGENIX-IDR-OM-02
Principal Investigator
Monica Shukla
Phase
II
Summary
This project is being done to test the safety and efficacy of SGX942 in patients with squamous cell carcinoma of the head and neck who will also receive treatment with chemotherapy and radiation therapy (also called chemoradiation therapy).
Description
SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: